CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII

Bone

Volumn 46, Issue 3, 2010, Pages 820-826

  Fratzl Zelman, N ^a   Morello, R ^b   Lee, B ^b,c   Rauch, F ^d   Glorieux, F H ^d   Misof, B M ^a   Klaushofer, K ^a   Roschger, P ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

Bone biopsy; CRTAP deficiency, Bone mineralization density distribution (BMDD); Mouse femur; Quantitative backscattered electron imaging (qBEI)

Indexed keywords

CARTILAGE ASSOCIATED PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; CRTAP PROTEIN, HUMAN; CRTAP PROTEIN, MOUSE; PROTEIN; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MINERAL; BONE MINERALIZATION; CANCELLOUS BONE; CONTROLLED STUDY; CORTICAL BONE; DEVELOPMENTAL DISORDER; FEMALE; FEMUR; GENE MUTATION; ILIAC BONE; KINETICS; MALE; NONHUMAN; OSTEOGENESIS IMPERFECTA; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; ANIMAL; BONE DENSITY; BONE MATRIX; C57BL MOUSE; CHILD; COMPARATIVE STUDY; DEFICIENCY; DISEASE MODEL; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; BONE DENSITY; BONE MATRIX; CALCIFICATION, PHYSIOLOGIC; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FEMUR; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OSTEOGENESIS IMPERFECTA; PROTEINS; UP-REGULATION;

EID: 77649182181     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.10.037     Document Type: Article

References (40)

1. Vranka J.A., Sakai L.Y., Bachinger H.P. Prolyl 3-hydroxylase 1, enzyme characterization and identification of a novel family of enzymes. J. Biol. Chem. 2004, 279:23615-23621.
2. Marini J.C., Cabral W.A., Barnes A.M., Chang W. Components of the collagen prolyl 3-hydroxylation complex are crucial for normal bone development. Cell. Cycle 2007, 6:1675-1681.
3. Myllyharju J., Kivirikko K.I. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet. 2004, 20:33-43.
4. Barnes A.M., Chang W., Morello R., Cabral W.A., Weis M., Eyre D.R., et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N. Engl. J. Med. 2006, 355:2757-2764.
5. Morello R., Bertin T.K., Chen Y., Hicks J., Tonachini L., Monticone M., et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006, 127:291-304.
6. Cabral W.A., Chang W., Barnes A.M., Weis M., Scott M.A., Leikin S., et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat. Genet. 2007, 39:359-365.
7. Bodian D.L., Chan T.F., Poon A., Schwarze U., Yang K., Byers P.H., et al. Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships. Hum. Mol. Genet. 2009, 18:463-471.
8. Sillence D.O., Senn A., Danks D.M. Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 1979, 16:101-116.
9. Rauch F., Glorieux F.H. Osteogenesis imperfecta. Lancet 2004, 363:1377-1385.
10. Camacho N.P., Landis W.J., Boskey A.L. Mineral changes in a mouse model of osteogenesis imperfecta detected by Fourier transform infrared microscopy. Connect Tissue Res. 1996, 35:259-265.
11. Fratzl P., Paris O., Klaushofer K., Landis W.J. Bone mineralization in an osteogenesis imperfecta mouse model studied by small-angle x-ray scattering. J. Clin. Invest. 1996, 97:396-402.
12. Misof K., Landis W.J., Klaushofer K., Fratzl P. Collagen from the osteogenesis imperfecta mouse model (oim) shows reduced resistance against tensile stress. J. Clin. Invest. 1997, 100:40-45.
13. Jones S.J., Glorieux F.H., Travers R., Boyde A. The microscopic structure of bone in normal children and patients with osteogenesis imperfecta: a survey using backscattered electron imaging. Calcif. Tissue Int. 1999, 64:8-17.
14. Boyde A., Travers R., Glorieux F.H., Jones S.J. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif. Tissue Int. 1999, 64:185-190.
15. Grabner B., Landis W.J., Roschger P., Rinnerthaler S., Peterlik H., Klaushofer K., et al. Age- and genotype-dependence of bone material properties in the osteogenesis imperfecta murine model (oim). Bone 2001, 29:453-457.
16. Misof B.M., Roschger P., Baldini T., Raggio C.L., Zraick V., Root L., et al. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone 2005, 36:150-158.
17. Carleton S.M., McBride D.J., Carson W.L., Huntington C.E., Twenter K.L., Rolwes K.M., et al. Role of genetic background in determining phenotypic severity throughout postnatal development and at peak bone mass in Col1a2 deficient mice (oim). Bone 2008, 42:681-694.
18. Weber M., Roschger P., Fratzl-Zelman N., Schoberl T., Rauch F., Glorieux F.H., et al. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 2006, 39:616-622.
19. Roschger P., Fratzl-Zelman N., Misof B.M., Glorieux F.H., Klaushofer K., Rauch F. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations. Calcif. Tissue Int. 2008, 82:263-270.
20. Glorieux F.H., Rauch F., Plotkin H., Ward L., Travers R., Roughley P., et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J. Bone. Miner. Res. 2000, 15:1650-1658.
21. Glorieux F.H., Ward L.M., Rauch F., Lalic L., Roughley P.J., Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J. Bone. Miner. Res. 2002, 17:30-38.
22. Ward L.M., Rauch F., Travers R., Chabot G., Azouz E.M., Lalic L., et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002, 31:12-18.
23. Cheung M.S., Glorieux F.H., Rauch F. Intravenous pamidronate in osteogenesis imperfecta type VII. Calcif. Tissue Int. 2009.
24. Roschger P., Fratzl P., Eschberger J., Klaushofer K. Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone 1998, 23:319-326.
25. Roschger P., Paschalis E.P., Fratzl P., Klaushofer K. Bone mineralization density distribution in health and disease. Bone 2008, 42:456-466.
26. Fratzl-Zelman N., Roschger P., Misof B.M., Pfeffer S., Glorieux F.H., Klaushofer K., et al. Normative data on mineralization density distribution in iliac bone biopsies of children, adolescents and young adults. Bone 2009, 44:1043-1048.
27. Ruffoni D., Fratzl P., Roschger P., Klaushofer K., Weinkamer R. The bone mineralization density distribution as a fingerprint of the mineralization process. Bone 2007, 40:1308-1319.
28. Ruffoni D., Fratzl P., Roschger P., Phipps R., Klaushofer K., Weinkamer R. Effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study. J. Bone Miner. Res. 2008, 23:1905-1914.
29. Vetter U., Fisher L.W., Mintz K.P., Kopp J.B., Tuross N., Termine J.D., et al. Osteogenesis imperfecta: changes in noncollagenous proteins in bone. J. Bone Miner. Res. 1991, 6:501-505.
30. Fedarko N.S., Robey P.G., Vetter U.K. Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta. J. Bone Miner. Res. 1995, 10:1122-1129.
31. Fedarko N.S., Vetter U., Robey P.G. The bone cell biology of osteogenesis imperfecta. Connect Tissue Res. 1995, 31:269-273.
32. Rauch F., Travers R., Parfitt A.M., Glorieux F.H. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 2000, 26:581-589.
33. Grzesik W.J., Frazier C.R., Shapiro J.R., Sponseller P.D., Robey P.G., Fedarko N.S. Age-related changes in human bone proteoglycan structure. Impact of osteogenesis imperfecta. J. Biol. Chem. 2002, 277:43638-43647.
34. Traub W., Arad T., Vetter U., Weiner S. Ultrastructural studies of bones from patients with osteogenesis imperfecta. Matrix Biol. 1994, 14:337-345.
35. Roschger P., Grabner B.M., Rinnerthaler S., Tesch W., Kneissel M., Berzlanovich A., et al. Structural development of the mineralized tissue in the human L4 vertebral body. J. Struct. Biol. 2001, 136:126-136.
36. Boivin G., Meunier P.J. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res. 2002, 43:535-537.
37. Boivin G., Meunier P.J. Methodological considerations in measurement of bone mineral content. Osteoporos. Int. 2003, 14(Suppl 5):S22-S27. discussion S27-8.
38. Misof B.M., Roschger P., Cosman F., Kurland E.S., Tesch W., Messmer P., et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J. Clin. Endocrinol. Metab. 2003, 88:1150-1156.
39. Rauch F., Travers R., Glorieux F.H. Cellular activity on the seven surfaces of iliac bone: a histomorphometric study in children and adolescents. J. Bone Miner. Res. 2006, 21:513-519.
40. Parfitt A.M., Travers R., Rauch F., Glorieux F.H. Structural and cellular changes during bone growth in healthy children. Bone 2000, 27:487-494.